Teladoc price target raised to $29 from $28 at Barclays

Barclays analyst Steve Valiquette raised the firm’s price target on Teladoc to $29 from $28 and keeps an Equal Weight rating on the shares. With a decent beat in Q1, Teladoc raised only the bottom end of its guidance, the analyst tells investors in a research note. The firm sees a slightly flatter EBITDA margin ramp as a result.